Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 19, 2026, 10:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neisseria Meningitidis Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine

NCT00129129
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine, ActHIB, Pediarix, Prevnar, Menomune
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
27
States / cities
Little Rock, Arkansas • Fountain Valley, California • Centennial, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba)

NCT02569632
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)
Biological
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Oakland, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of Age

NCT00345579
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014, ActHIB, Pediarix/Infanrix Penta
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
4,432 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
61
States / cities
Birmingham, Alabama • Benton, Arkansas • Fayetteville, Arkansas + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Azithromycin for Meningococcal Carriage

NCT06618534
View directory record Official record
Conditions
Meningococcal Infections
Interventions
Azithromycin
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
764 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose Comparison Study of Menactra® in US Children

NCT00700635
View directory record Official record
Conditions
Meningitis, Meningococcal Infection, Neisseria Meningitidis
Interventions
Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
2 Years to 10 Years
Enrollment
333 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
15
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boca Raton, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB

NCT00359983
View directory record Official record
Conditions
Neisseria Meningitidis, Haemophilus Influenzae Type b
Interventions
MenHibrix (Hib-MenCY-TT), Hib conjugate vaccine (ActHIB)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
22 Months to 60 Months
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2011
U.S. locations
21
States / cities
Little Rock, Arkansas • Fountain Valley, California • Norwich, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®

NCT00269477
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
15 Years to 23 Years
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
8
States / cities
Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2016 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2, Observer-Blind, Placebo-Controlled, Randomized, Multi-Center Extension Study to Evaluate the Safety and Immunogenicity of a Booster Dose of a MenABCWY Vaccine Administered 24 Months Following the Primary Series to Adolescents and Young Adults Who Participated in V102_03 (NCT01272180)

NCT01992536
View directory record Official record
Conditions
Meningococcal Disease
Interventions
MenABCWY+OMV, MenABCWY+¼OMV, Placebo
Biological
Lead sponsor
Novartis Vaccines
Industry
Eligibility
10 Years to 25 Years
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
8
States / cities
Birmingham, Alabama • Madera, California • Paramount, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®

NCT00258856
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Polysaccharide Diphtheria Conjugate Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
7 Years to 15 Years
Enrollment
234 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
11
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Marietta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine

NCT00772070
View directory record Official record
Conditions
Meningitis, Meningococcemia, Neisseria Meningitidis
Interventions
A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
3 Years to 5 Years
Enrollment
173 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2004
U.S. locations
8
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Woburn, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

NCT00614614
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix), GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix), Infanrix®, ActHIB®, Pediarix®
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,558 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
56
States / cities
Birmingham, Alabama • Dothan, Alabama • Benton, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2018 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Assess Gonorrhoeae Immune Responses Induced by a N. Meningitidis Vaccine

NCT04094883
View directory record Official record
Conditions
Neisseria Gonorrhoeae Infection
Interventions
Meningococcal Group B Vaccine
Biological
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 25 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Jul 19, 2026, 10:20 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults

NCT07197762
View directory record Official record
Conditions
Neisseria Meningitidis
Interventions
Trumenba, PENBRAYA
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 25 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AV0328 Administered to Healthy Adult Volunteers

NCT02853617
View directory record Official record
Conditions
PNAG-expressing Pathogenic Microbes Vaccine
Interventions
AV0328 - Cohort 1, AV0328 - Cohort 2, AV0328 - Cohort 3, AV0328 - Cohort 4
Biological
Lead sponsor
Alopexx Vaccine, LLC
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

NCT00345683
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014), PedvaxHIB, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Months to 15 Months
Enrollment
4,021 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
55
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Phase 1 Safety and Immunogenicity of Meningococcal Vaccine

NCT00678652
View directory record Official record
Conditions
Meningococcal Infection, Group B
Interventions
10 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 25 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 50 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine, 75 μg Group B Meningococcal 8570 HOPS-G NOMV Vaccine
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2017 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

NCT00289783
View directory record Official record
Conditions
Haemophilus Influenzae Type b, Neisseria Meningitidis
Interventions
GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine, ActHIB, PedvaxHIB, Pediarix, Prevnar, M-M-R II, Varivax
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Weeks to 15 Months
Enrollment
4,441 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
88
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®

NCT00355121
View directory record Official record
Conditions
Meningococcal Meningitis, Tetanus, Diphtheria, Pertussis, Poliomyelitis
Interventions
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Biological
Lead sponsor
Sanofi
Industry
Eligibility
4 Years to 7 Years
Enrollment
882 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
26
States / cities
Little Rock, Arkansas • Boulder, Colorado • Atlanta, Georgia + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects

NCT01641042
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
1 Year to 17 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
14
States / cities
Antioch, California • Daly City, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine

NCT00777257
View directory record Official record
Conditions
Meningitis, Meningococcemia, Pertussis, Tetanus, Diphtheria
Interventions
T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj., Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
11 Years to 17 Years
Enrollment
1,345 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
20
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Boulder, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers

NCT01049035
View directory record Official record
Conditions
Meningitis, Meningococcal Infection
Interventions
Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus B Conjugate (Tetanus Toxoid Conjugate) Vaccine Combined (DTaP-IPV/Hib combined), M-M-RII-Measles, Mumps, and Rubella Virus Vaccine Live, Varicella Virus Vaccine Live, Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Pneumococcal 13-valent Conjugate Vaccine (Diphtheria CRM197 Protein), Rotavirus Vaccine, Hepatitis B Vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
42 Days to 365 Days
Enrollment
580 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
25
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Jonesboro, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents

NCT00777790
View directory record Official record
Conditions
Meningitis, Meningococcemia
Interventions
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
13 Years to 21 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
9
States / cities
Atlanta, Georgia • Marietta, Georgia • Woburn, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.

NCT00471081
View directory record Official record
Conditions
Infections, Meningococcal
Interventions
Meningococcal vaccine GSK134612
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
9 Months to 9 Months
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
19
States / cities
Birmingham, Alabama • Benton, Arkansas • Little Rock, Arkansas + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2019 · Synced Jul 19, 2026, 10:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity and Safety Study of GSK's MenABCWY Vaccine in Healthy Adolescents and Adults Previously Primed With MenACWY Vaccine

NCT04707391
View directory record Official record
Conditions
Meningitis, Meningococcal
Interventions
MenABCWY vaccine, Placebo, MenACWY vaccine, MenB vaccine
Combination Product · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
15 Years to 25 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
48
States / cities
Jonesboro, Arkansas • Banning, California • Chula Vista, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 19, 2026, 10:20 AM EDT